The SOX2 status of disseminated tumor cells in breast cancer patients treated with neoadjuvant chemotherapy

Natalia Krawczyk*, Kathrin Janowski, Maggie Banys-Paluchowski, Annette Staebler, Hans Neubauer, Christoph Meisner, Andreas Hartkopf, Sara Brucker, Diethelm Wallwiener, Tanja Fehm

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

Background/Aim: Detection of disseminated tumor cells (DTCs) after systemic treatment predicts poor prognosis in breast cancer patients. The aim of our study was to assess the expression of stem-cell marker SOX2 on DTCs and in the primary tumor of patients treated with neoadjuvant chemotherapy (NAT). Materials and Methods: In 170 DTCpositive patients after NAT an additional slide of bone marrow aspirate was stained by double immunofluorescence to detect SOX2-positive DTCs. The SOX2 status of the primary tumor was assessed using the same antibody. Results: The SOX2-status of DTCs was determined in 62 patients and 20 of those (32%) had SOX2 positive DTCs. The SOX2 status of DTCs was not associated with any of the clinicopathological factors. A total of 36% of the patients with a SOX2-negative tumor showed SOX2-positive persistent DTCs. Conclusion: SOX2-positive DTCs can be detected in breast cancer patients after NAT, even in patients with SOX2-negative primary tumors. This suggests that these populations may have evolved independently of each other.

OriginalspracheEnglisch
ZeitschriftAnticancer Research
Jahrgang41
Ausgabenummer6
Seiten (von - bis)2849-2858
Seitenumfang10
ISSN0250-7005
DOIs
PublikationsstatusVeröffentlicht - 06.2021

Strategische Forschungsbereiche und Zentren

  • Profilbereich: Lübeck Integrated Oncology Network (LION)
  • Zentren: Universitäres Cancer Center Schleswig-Holstein (UCCSH)

Fingerprint

Untersuchen Sie die Forschungsthemen von „The SOX2 status of disseminated tumor cells in breast cancer patients treated with neoadjuvant chemotherapy“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren